Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Exact Sciences Corporation

$104.91

-0.02 (-0.02%)

D 34Pipeline Score Diagnostics · Commercial
Market Cap
20.03 B
EPS
-1.10
P/E Ratio
-
Value Trade
2.26 B
SEC Financials
Q4 2025

  • Dilution Risk

    5%

  • Revenue

    878.38 M

  • R&D Expenses

    191.50 M

  • Operating CF

    122.86 M

  • Total Assets

    5.86 B

  • Total Liabilities

    3.46 B

  • Equity

    2.40 B

  • D/E Ratio

    12,345

1.33 %
Week
1.55 %
1 Month
3.36 %
3 Month
96.53 %
6 Month
-18.67 %
5 Year
611.25 %
All Time
Cash Data
Profitable

  • Cash Position

    964.71 M

  • Monthly Burn

    -

  • Runway

    12,345 mo

  • Burn Trend

    Decelerating

  • SEC Filing

    Feb 13, 2026
Overview
Volume
21.56 M
52 Week Range
38.81 - 104.98
% held by Insiders
1.59 %
% held by Institutions
86.16 %
Enterprise Value
21.60 B
Total Shares
189.38 M
Short %
4.18 %
Float Shares
187.67 M
Company Description
HQ: 5505 ENDEAVOR LANE, MADISON, W...
Founded:1995
Employees:7,200
https://www.exactsciences.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
PDUFA 2026
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%

FDA review of the new drug application for the treatment of example condition.

Read More
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%

FDA review of the new drug application for the treatment of example condition.

Read More
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%

FDA review of the new drug application for the treatment of example condition.

Read More
Small Molecule
Oncology
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
D34
Pipeline Score
$357M
Pipeline Value
Valuation Signal
2
Drugs Scored
0.0x
rNPV / MCap
Top 45%
Mid Cap
(rank 502 of 911)
Percentile Rank
Exact Sciences Corporation faces pipeline headwinds (34/100), with $420M risk-adjusted pipeline value, led by Ribociclib in Breast Cancer Female (Phase 3).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
Ribociclib
Small molecule		Breast Cancer FemalePhase 3NCT0405549346% $265M ACTIVE NOT_RECRUITING 1,684 - -Jul 31, 2027 -
May 21, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
Oncodetect®
early triple-negative breast cancer
—
2026-03-17

Pre-surgery ctDNA status following neoadjuvant therapy (NAT) was strongly associated with both pathologic complete response (pCR) and distant recurrence-free interval (dRFI).

Read More

Exact Sciences to Present New Molecular Residual Disease and Multi-Cancer Early Detection Data at AACR 2026

Read More
Oncodetect®
early triple-negative breast cancer
—
2026-03-17

Pre-surgery ctDNA status following neoadjuvant therapy (NAT) was strongly associated with both pathologic complete response (pCR) and distant recurrence-free interval (dRFI).

Read More

Exact Sciences to Present New Molecular Residual Disease and Multi-Cancer Early Detection Data at AACR 2026

Read More
Oncodetect®
early triple-negative breast cancer
—
2026-03-17

Pre-surgery ctDNA status following neoadjuvant therapy (NAT) was strongly associated with both pathologic complete response (pCR) and distant recurrence-free interval (dRFI).

Read More

Exact Sciences to Present New Molecular Residual Disease and Multi-Cancer Early Detection Data at AACR 2026

Read More
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in EXAS
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
EXAS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How EXAS ranks across every disease it competes in
Competitive Position is a premium feature
See how EXAS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial